[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:u2af1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"U2AF1 Gene",10,9,[8,16,23,29,35,41,47,53,60,66],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05641831","Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study",[12],"Phase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.648361Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[20],"Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06313437","Revumenib in Combination With 7+3 + Midostaurin in AML",[20],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.835411Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04659616","Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[20],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.717298Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06152809","CIML NK Cells With Venetoclax for AML",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06366789","Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.326010Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT03013998","Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",[57],"Phase 1\u002FPhase 2","2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.183972Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04588922","Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML",[57],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:28.806272Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT05732961","Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS\u002FMPN Neoplasms",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:59:02.155507Z","2026-05-05T02:43:28.651417Z"]